Notice Regarding Additional Contribution for the Continuation of the Share-Based Compensation Plan for Directors and Officers
Filed with TSE · · 2 pages · English
Summary by 6ix AI
Shimadzu Corporation has issued a notice regarding an additional contribution for the continuation of its share-based compensation plan for directors and officers. The company plans to make this additional contribution to acquire shares expected to be delivered during the new trust period. Details of the trust agreement following this contribution include the purpose of providing incentives to directors and officers.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Shimadzu
- Shimadzu: CVC Fund “Shimadzu Future Innovation Fund” Invests in OptQC, a Developer of Optical Quantum ComputersExpected to Advance Next-Generation R&D Infrastructure for Drug Discovery and Materials Development
- Consolidated Financial Results for the Three Months Ended June 30, 2026 (Under Japanese GAAP)
- Shimadzu Acquires Czech-Based TESCAN as a Wholly Owned SubsidiaryAcquisition of Electron Microscopy Business Strengthens End-to-End Solutions in Analytical and Measuring Technologies
- Shimadzu Medical Systems USA announces the release of the FLUOROspeed X1 edition ST
- New Medium-Term Management Plan for FY 2026 to 2028 PreparedBecome an Innovative Company That Solves Social Challenges Together with Global Partners—Sustainably Improve Profitability by Strengthening End-to-End Solutions Capabilities—
Later from Shimadzu
- Reorganization of UK Group Companies; Business Operations Commence Under New Structure Enhancing Development Capabilities for Mass Spectrometers and X-ray Photoelectron Spectroscopy Instruments
- CVC Fund "Shimadzu Future Innovation Fund"Invested in Kinish, which is working on next-generation food development utilizing plant molecular agriculture technology
- Shimadzu: Thailand's Deputy Prime Minister Visits Shimadzu CorporationShimadzu Signs Letter of Intent with Thai Research Institutions for Cooperation in Research and Innovation
- Supporting Biopharmaceutical Development through AI-Powered Cell Culture Media OptimizationShimadzu Begins Collaboration with Axio BioPharma
- Consolidated Financial Results for the Six Months Ended September 30, 2026 (Under Japanese GAAP)
Follow Shimadzu into a list and get an email when it puts out news.
Follow Shimadzu